An Early Phase 1 interventional study of Rifaximin 200 mg and Standard Treatment without Rifaximin in Liver Failure, Acute on Chronic, Hepatic Encephalopathy and HBV, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-28.
Sponsored by Sun Yat-sen University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Acute-On-Chronic Liver Failure with a site in China — 18 open to participants now, 22 under way, none of them phase 3. Acute-On-Chronic Liver Failure · China.
Among the 48 studies in Acute-On-Chronic Liver Failure with a site in China, this one is the 8th largest by planned enrollment of the 25 interventional ones that give a count, is one of 12 that started in 2023, is one of 5 in phase 1, reaches primary completion later than 10 of the 21 other live ones, and was the 30th registered.
167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.
Browse Acute-On-Chronic Liver Failure studies →18 of the 48 studies in Acute-On-Chronic Liver Failure with a site in China are open now. Recruiting first, the newest first:
Shenzhen Third People's Hospital · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18+
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–70
RenJi Hospital · Sites in China
Ages 18–65
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 8 · Phase 4 1
First in 2007; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 124 is above the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.
Median enrollment 80 across the 25 interventional studies, 411 across the 23 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 48 have an industry lead sponsor. The 10 most frequent:
Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.
Sun Yat-sen University has 3 studies filed under Acute-On-Chronic Liver Failure — fewer than ten, so there is no comparison to draw.
5 of the studies in Acute-On-Chronic Liver Failure with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05985863Beijing 302 HospitalHuman Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure | 2026-12-30 |
| NCT06996392Third Affiliated Hospital, Sun Yat-Sen UniversityPhase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure | 2026-12-31 |
| NCT07409259Third Affiliated Hospital, Sun Yat-Sen UniversityPT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure | 2027-08-31 |
| NCT06562803Third Affiliated Hospital, Sun Yat-Sen UniversityEfficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis | 2027-10-31 |
| NCT06916585Shenzhen Third People's HospitalChinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patients | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies in Acute-On-Chronic Liver Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There will be 124 patients diagnosed as hepatitis B associated acute on chronic liver failure with mild to moderate hepatic encephalopathy will be enrolled in this study according to the inclusion and exclusion criteria, and will be randomly divided into two groups as 1:1.First group is called Rifaximin group, on the basis of comprehensive treatment of liver failure, Rifaximin (Alfa Sigma S.p.A) is added, three times a day, 400 mg each time, for a total of 4 weeks, and observed until 12 weeks after withdrawal. The other group is called standard treatment group (control group), which will receive routine comprehensive treatment for liver failure. The reversal of mild to moderate hepatic encephalopathy in the two groups of patients will be observed within 4 weeks, then follow up to 12 weeks.
Liver failure is a common clinical syndrome of severe liver disease, with a high mortality rate. On the basis of chronic liver disease, acute on chronic liver failure is a syndrome characterized by acute jaundice deepening and coagulation dysfunction caused by various inducements, which can be combined with hepatic encephalopathy, ascites, electrolyte disorder, infection, hepatorenal syndrome, hepatopulmonary syndrome and other complications, as well as extrahepatic organ failure. At present, the medical treatment of acute on chronic liver failure is still lacks of efficient drugs and means. On the other hand, the mortality rate of liver transplantation can be as high as 50-70%. The occurrence of bacterial infection, hepatic encephalopathy, hepatorenal syndrome and other complications is significantly related to the high mortality of acute on chronic liver failure. Common causes of liver failure include hepatitis virus, drugs or hepatotoxic substances, autoimmune diseases, etc. In China, hepatitis B virus infection is the main cause of acute on chronic liver failure.
Previous studies have confirmed that intestinal flora imbalance and translocation are important reasons for decompensated cirrhosis complicated with primary bacterial peritonitis. Gram-positive bacteria (including enterococcus, staphylococcus, etc.) and multidrug resistant bacteria have become common pathogenic bacteria of spontaneous bacterial peritonitis. A randomized controlled clinical study on spontaneous bacterial peritonitis in Europe shows that gram-positive bacteria account for 62.5% of bacteria isolated from ascites, enterococcus accounted for the majority. The intestinal flora imbalance and translocation are also important inducements of decompensated cirrhosis complicated with hepatic encephalopathy and hepatorenal syndrome. Patients with acute on chronic liver failure also have intestinal flora imbalance. Recent research shows that the proportion of enterococci in hepatitis B associated acute on chronic liver failure is significantly increased, and during the progress of hepatitis B associated acute on chronic liver failure, enterococcus faecium rapidly increases, which is related to poor prognosis. Due to the severe inflammatory reaction, patients with acute on chronic liver failure are prone to intestinal barrier function defects. Therefore, intestinal flora imbalance and translocation are closely related to the complications of acute on chronic liver failure complicated by bacterial infection and hepatic encephalopathy.
Rifaximin- α (referred to as Rifaximin) is a drug that is not easy to be absorbed and only works locally in the gastrointestinal tract. The concentration in the intestinal tract is much higher than MIC90 of the intestinal flora. It has broad-spectrum antibacterial activity, can cover gram-positive and gram-negative bacteria, and is not conducive to the screening of drug-resistant strains. The efficacy and safety of Rifaximin in the prevention and treatment of hepatic encephalopathy in patients with decompensated cirrhosis have been confirmed by many large randomized controlled clinical trials worldwide, and it is the only drug approved by FDA in the United States for the treatment and prevention of hepatic encephalopathy in the past 30 years. Over the past 10 years, experimental and clinical evidence has shown that Rifaximin may have other beneficial effects on the course of liver cirrhosis by regulating intestinal microflora and affecting the gut-liver axis. Rifaximin has been reported for the prevention of other complications of cirrhosis, including spontaneous bacterial peritonitis, hepatorenal syndrome, reduction of portal pressure, prevention of bleeding from esophageal varices, and treatment of refractory ascites in cirrhosis.
In the drug information about Rifaximin released by the FDA of the United States, it was mentioned that patients with severe liver damage (Child-Pugh C) should be cautious in use, because in the clinical experiment of using rifaximin to prevent and treat hepatic encephalopathy, it was found that rifaximin 550 mg/time, twice a day, for patients with Child-Pugh score A, B and C, the amount of drugs entering the systemic circulation was 10 times higher than that of the healthy control group (12.3 ± 4.8 ng • h/mL), 14 times and 21 times (257 ± 100.2 ng • h/mL).Therefore, most previous clinical trials only included patients with MELD score less than 25. Although the systemic exposure of patients with severe liver damage was higher than that of the healthy control group, due to the low total exposure, the side effects of Rifaximin were rare in the clinical study of decompensated cirrhosis, and the incidence of adverse events was similar to that of the control group. Because Rifaximin mainly takes effect locally in the intestine, the systemic bioavailability is low, and the safety data of Rifaximin in patients with liver cirrhosis, FDA does not recommend adjusting the dose for patients with severe liver damage, and the drug instructions also indicate that dose adjustment is not necessary for patients with liver insufficiency.
A recently published multicenter exploratory study suggested that the use of rifaximin in patients with severe alcoholic hepatitis (MELD score 19-24) was safe, and compared with the control group, the use of Rifaximin could reduce the incidence of infection and the incidence of infection-related acute on chronic liver failure after the use of glucocorticoids in severe alcoholic hepatitis. However, the safety and efficacy of Rifaximin in patients with hepatitis B (HBV) associated acute on chronic liver failure have not been reported. Our study plans to evaluate the safety and effectiveness of Rifaximin in the treatment of hepatitis B(HBV) associated acute on chronic liver failure complicated with mild to moderate hepatic encephalopathy through a randomized controlled study.
There will be 124 patients diagnosed as hepatitis B associated acute on chronic liver failure with mild to moderate hepatic encephalopathy will be enrolled in this study according to the inclusion and exclusion criteria, and will be randomly divided into two groups as 1:1.First group is called Rifaximin group, on the basis of comprehensive treatment of liver failure, Rifaximin (Alfa Sigma S.p.A) is added, three times a day, 400 mg each time, for a total of 4 weeks, and observed until 12 weeks after withdrawal. The other group is called standard treatment group (control group), which will receive routine comprehensive treatment for liver failure. The reversal of mild to moderate hepatic encephalopathy in the two groups of patients will be observed and recorded within 4 weeks, then follow up to 12 weeks. The occurrence of various complications related to liver failure and survival situation will be recorded within 12 weeks, during this time, serum of the two groups of patients will be collected, and the changes of biochemical and coagulation indicators and the changes of serum bacterial translocation-related markers will be recorded. The feces of patients before and after treatment will be collected for intestinal microecological analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The confirmed positive patients with chronic hepatitis B are defined as HBsAg positive for at least 6 months or evidence of chronic HBV infection;
There are definite infections or hepatorenal syndromes during screening;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rifaximin 200 mg
Other: Standard Treatment without Rifaximin
Rifaximin Treatment Group:on the basis of comprehensive treatment of liver failure, Rifaximin will be added, three times a day, 400mg each time, for a total of 4 weeks, and we will observe until 12 weeks after withdrawal.
The standard treatment group (control group), which will receive routine comprehensive treatment for liver failure without Rifaximin.
The reversal rate of hepatic encephalopathy between 2 groups in 4 weeks.
The reversal rate of hepatic encephalopathy in the 2 groups within 4 weeks will be recorded.
Time frame: 4 weeks
The incidence of complications related to liver failure within 12 weeks between 2 groups.
The incidence of complications related to liver failure will be recorded in the 2 groups during 12 weeks.
Time frame: 12 weeks
The survival rate between 2 groups within 12 weeks.
The survival rate will be observed in the two groups within 12 weeks.
Time frame: 12 weeks
Plan to share: No
Started Mar 2023 (actual). Primary completion is estimated for Jul 2025, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Acute-On-Chronic Liver Failure →